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Irritable bowel syndrome is a group of functional gastrointestinal disorders with not yet fully clarified etiology. Recent evidence 
suggesting that mast cells may play a central role in the pathogenesis of irritable bowel syndrome paves the way for agents targeting 
histamine receptors as a potential therapeutic option in clinical treatment. In this review, the role of histamine and histamine receptors 
is debated. Moreover, the clinical evidence of anti-histamine therapeutics in irritable bowel syndrome is discussed.
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Introduction  
Irritable bowel syndrome (IBS) is a functional gastrointestinal 
(GI) disorder without completely elucidated etiology. The typical 
symptoms are abdominal pain and change in bowel habits. Addi-
tionally, bloating, tenesmus, bowel urgency, and abdominal disten-
sion can occur. A recent meta-analysis estimated the international 
prevalence of IBS at 11.2%1 based on the Rome III criteria; how-
ever, a recent study in China showed that the number of patients 
diagnosed based on the Rome IV criteria is nearly half the number 
of patients diagnosed according to the Rome III criteria.2 However, 
only one-third of those who suffer from IBS-like symptoms see a 
physician, the actual prevalence may be much higher. IBS impairs 
the quality of life in patients to a similar degree as in patients with 
inflammatory bowel diseases3 and the impairment is proportional to 
the severity of the symptoms experienced by the patient.4
IBS is a heterogeneous entity with etiology comprising of 
multiple factors such as inflammation, neuroimmune interactions,5 
gut microbiota,6 environmental pollution,7 and abnormal gut-brain 
axis.8 This heterogeneity has a significant impact on treatment. As 
the disease profile may vary between the patients, the treatment 
should be personally tailored with regard to predominant symptoms 
and disease characteristics. It is particularly crucial due to the pleth-
ora of drugs available on the market nowadays.9 However, despite 
the number of drugs available the treatments are not fully satisfac-
tory in all patients. Also, the symptoms eventually relapse.
A large portion of both established and investigated treatment 
options include drugs based on serotonin (5-hydroxytryptamine, 
5-HT). Indeed, 5-HT plays an important role in the gut by affect-
ing motility and secretion.10 Moreover, it was recently found that 
alterations in 5-HT metabolism may be implicated in visceral hy-
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persensitivity, which is an important feature of IBS.11 Interestingly, 
in a study performed by Cremon et al12 the lamina propria mast cell 
(MC) count positively correlates with the increase in spontaneous 
5-HT release in patients with IBS. While serotonin has already 
proven to be implicated in the pathogenesis of IBS, histamine is 
emerging as an important biogenic amine in this disease. Although 
the pathophysiological role of histamine in IBS is not entirely clear, 
there is evidence that supports the use of agents targeting the his-
tamine receptors (HRs) as a potential therapeutic option in these 
patients. In this review, the role of histamine and HRs in IBS is 
critically appraised. Moreover, the possible use of anti-histamine 
therapeutics is discussed.
Overview of Histamine and Histamine  
Receptors in the Gastrointestinal Tract  
Histamine (2-[4-imidazolyl]-ethylamine) is a short-acting en-
dogenous amine, which is widely distributed in the human body.13 
Histamine is synthesized by the enzyme histidine decarboxylase in 
all human tissues, but is particularly abundant in the skin, lungs, 
and GI tract.14
Histamine is produced mainly by MCs and, to a lesser extent, 
by basophils, gastric enterochromaffin-like cells, and histaminergic 
neurons.15,16 However, platelets, dendritic cells (DCs), T cells, and 
even microbes can also express histidine decarboxylase following 
a stimulation by cytokines, including IL-1, IL-3, IL-12, IL-18, 
granulocyte-macrophage colony-stimulating factor, macrophage 
colony-stimulating factor, and TNF-α.13,17,18 Only MCs and baso-
phils are capable of storing large quantities of histamine. Other cell 
types such as DCs and lymphocytes do not store histamine intracel-
lularly but the synthesis is followed by an immediate secretion.
Histamine is involved in several physiological functions, includ-
ing cell proliferation and differentiation, hematopoiesis, regenera-
tion, and the regulation of innate and adaptive immune systems.19 
Histamine exerts its biological actions by binding to 4 subtypes of 
HRs, which are named chronologically in order of their discovery: 
H1R-H4R. These 4 binding sites belong to the rhodopsin-like 
family of G protein-coupled receptors, which are differentially ex-
pressed in numerous cell types. Although all 4 HRs are expressed 
in the human body, the intestines seem to be devoid of H3Rs.
20 The 
expression pattern of HRs does not change anatomically along the 
intestine.
In the GI tract, histamine is believed to impact at least 3 major 
functions: modulation of GI motility, enhancement of gastric acid 
production, and alteration of mucosal ion secretion.21-23 H1Rs are 
involved in mediating sensorineural signaling and vascular dilata-
tion.24 Activation of H1R is known to regulate food and water 
intake and diurnal feeding rhythm.25 Stimulation of H2R results 
in degranulation of MCs, synthesis of antibodies, production of T 
helper (Th) 1 cytokines, and T-cell proliferation.16,26 H4R plays a 
significant role in nociception, autoimmune disorders, colon cancer, 
and allergy.27-29 Clear interpretation of histamine involvement in 
regulation of GI motility is currently lacking. However, the evi-
dence indicates that overproduction of histamine by MCs may be 
responsible for diarrhea caused by increased neuronal secretomotor 
function.30 Another hypothesis assumes that in constipated patients 
histamine induces altered enteric neuron function as a result of an 
excessive segmental contractile colonic motor activity.31 However, 
the pathological relevance of increased histamine levels in diseases, 
such as IBS, is not yet fully elucidated. 
Table 1 describes the localization and role of specific HRs in 
the GI tract. Localization of HRs in the intestinal wall is depicted 
Table 1. Localization and Role of Specific Histamine Receptors in the Gastrointestinal Tract
Receptors Localization Role
H1 Enterocytes, connective tissue cells, immune cells,  
blood vessels, myocytes, and myenteric plexus
Regulation of diurnal feeding rhythm, mediation of sensorineural 
signaling, control of vascular dilatation and permeability, impact  
on gastrointestinal contractility and motility, and modulation of  
visceral pain
H2 Enterocytes, immune cells, myocytes, and myenteric plexus Immunomodulatory properties and control of gastrointestinal  
contractility and motility
H3 Not found in the human gastrointestinal tract
H4 Lamina propria mononuclear cells and intestinal mast cells, 
leukocytes in mucosal and submucosal blood vessels, and 
enterocytes in the apical end of intestinal glands
Immunomodulatory properties, impact on gastrointestinal  
contractility and motility, and modulation of visceral pain
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in Figure.
Irritable Bowel Syndrome and Histamine  
The summary on animal and human studies with MCs and 
HRs as targets is shown in Table 2.32-41
The etiology and the pathophysiology are only partly under-
stood, with some evidence suggesting that intestinal infections, and 
dysfunctional mucosal immune responses may play a role in the 
development of IBS and its symptoms.
Patients with IBS frequently experience post-prandial worsen-
ing of their symptoms. Moreover, a vast majority of IBS patients 
feel that distinct foods play pivotal role in triggering their symp-
toms. In a recent study,42 58% of patients with IBS experienced GI 
symptoms from histamine-releasing food items such as milk, wine 
or beer, and foods rich in biogenic amines (wine, beer, and cheese). 
Interestingly, the use of spherical carbon adsorbents, known for ad-
sorbing molecules (for instance histamine) from the gut lumen has 
been proven to be beneficial in some patients.41 
High levels of histamine were found in supernatants from IBS 
colonic samples.43 Application of this supernatant to rat submucous 
neurons resulted in increased neuronal activity. Furthermore, posi-
tive correlation between histamine levels in the supernatant and 
the degree of activation was stated.44 The neuronal response of 
submucous neurons to the artificially designed cocktail, which is a 
combination of mucosal and immune mediators mimicking nerve 
activating components found in colonic biopsy supernatants and se-
rum of IBS-patients, was lower in mucosal IBS biopsies compared 
to healthy controls.45 This effect appears in IBS most likely due to 
the desensitization to mediators, which is caused by the chronic 
contact of the gut wall with the mediators found in the gut lumen. 
Additionally, histamine induced murine jejunal afferent firing and 
excited primary sensory neurons.46,47 According to the study of 
Barbara et al,43 the pronociceptive effect of histamine appears to be 
mediated, at least partly, by H1R expressed on sensory afferents. 
In contrast, Guarino et al48 found that supernatants from patients 
with IBS impair contractility of isolated human colonic smooth 
muscles and the phenomenon is histamine-independent. The effect 
was significantly reversible by apocynin, a nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase inhibitor, suggesting 
the intracellular oxidative stress damage to be the main cause of this 
contractility impairment.
The expression of H1R and H2R in the intestinal tissue sam-
ples of IBS patients is upregulated.20 Moreover, it has been reported 
that H1R activation results in proinflammatory effects such as IFN 
production and Th1 cell proliferation, while H2R activation appears 
to suppress inflammation.19,49,50 Activation of H2R by histamine 
suppresses IL-12 production by monocytes,51 IFN-γ production by 
macrophages,52 TNF-α secretion by MCs,53 and IL-12 release by 
immature DCs.54 In vivo studies showed that histamine suppresses 
both Th1- and Th2-type responses by H2R.
55 It is noteworthy that 
in colonic biopsies of IBS patients or patients with food allergy, no 
alterations in H4R mRNA levels were reported.
20 However, in-
volvement of the H4R in visceral sensory signaling and GI contrac-
tility has been documented56; yet, more studies are needed to fully 












Figure. Localization of histamine re-
ceptors in the intestinal wall.
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There is a large body of evidence suggesting that MCs are an 
important factor in the pathophysiology of IBS.39 IBS patients have 
an increased number of MCs, which contain granules rich in medi-
ators such as histamine, tryptase, and nerve growth factors that can 
activate and sensitize enteric nerves, and modulate the integrity of 
the epithelial barrier.57,58 An increased number of mucosal MCs has 
been observed in biopsy samples from the rectum,59 rectosigmoid,60 
descending colon,43 ascending colon,59 cecum,61 terminal ileum,59 
jejunum,62 and duodenum63 of patients with IBS. Also, the level of 
activation and intensity of MCs degranulation is increased. Acti-
vated MCs spontaneously secreting higher amounts of histamine 
in close proximity to colonic nerves correlated with severity and fre-
quency of abdominal pain in IBS patients.31 According to the study 
of Cremon et al64 it is possible that the number of functionally active 
MCs is more important in IBS, rather than the absolute number 
of cells. The recent review by Zhang et al65 profoundly embraces all 
aspects of MCs in IBS.
Possible Application of Anti-histamine 
Drugs in Irritable Bowel Syndrome  
Abdominal pain, often described as discomfort, is believed to 
be linked to visceral hypersensitivity which seems to be multifacto-
rial.66,67 MCs and histamine seem to contribute majorly to visceral 
hypersensitivity. A study on H1R knockout mice showed that they 
are more prone to visceral pain, measured by abdominal stretch-
ing after intraperitoneal injection of either acetic acid or MgSO4 
than their wild type littermates.68 A study in the rat model of IBS 
induced by acetic acid revealed a higher degranulation rate of MCs 
in the colon from rats with IBS-like symptoms. Moreover, pretreat-
ment with a MC stabilizer, doxantrazole, decreased visceral sensory 
response to rectal distention in these rats.69 Finally, histamine was 
shown to activate enteric neurons through H1 and H2 recep-
tors.70,71 
MCs with their stored enzymes are important players in dys-
regulated brain-gut axis. Thus, targeting MCs or HRs arises as a 
potent treatment option for selected patients with IBS. A few clini-
cal studies have addressed this hypothesis. Klooker et al38 attempted 
to translate the research on the use of MC stabilizers in IBS from 
animals33 to humans. The randomized double-blinded controlled 
trial showed that ketotifen increased tolerance to abdominal discom-
fort in patients with IBS with visceral hypersensitivity, improved 
symptoms and the quality of life. However, no effect on the number 
of MCs, release of tryptase and histamine from rectal biopsies could 
be demonstrated. Since ketotifen is a H1 receptor antagonist, an 
MC stabilizer, a phosphodiesterase inhibitor and a functional leu-
kotriene inhibitor, it was not completely evident which of its features 
was responsible for the anti-IBS effects. Therefore, MC stabiliza-
tion and H1R blockade could be further explored as potential new 
treatments for IBS.
A recent study showed that by blocking H1R with ebastine, a 
second generation H1R antagonist, attenuation of visceral hyper-
sensitivity and other IBS symptoms could be achieved.39 Interest-
ingly, the transient receptor potential vanilloid 1 (TRPV1) was 
found to be implicated in the process; either histamine alone or the 
supernatant from rectal biopsies from patients with IBS sensitize 
TRPV1 channels. Upon activation by stimuli such as noxious heat, 
acidosis or endovanilloids, TRPV1 becomes non-selectively perme-
able for ions. It is most likely that sensitization lowers the threshold 
for channel activation possibly leading to activation by the normal 
body temperature. The involvement of TRPV1 in IBS has been 
investigated before. Akbar et al60 discovered increased sensory fi-
bers which express TRPV1 channel in patients with IBS. Also, the 
results from animal studies suggested the contribution of TRPV1 
in visceral hypersensitivity.72,73 However, TRPV1 is distinctive, 
involved in both physiological and pathophysiological actions in the 
human body, such as maintaining proper lower urinary tract func-
tion.74 Thus, prior to the discovery of a crosstalk between MCs and 
TRPV1, it was unreasonable to talk about the TRPV1 as a stand-
alone therapeutic target. Now, as the connection between the two 
became apparent, it is easier to indicate plausible therapeutic agents.
The aforementioned HR antagonists are without doubt a 
part of that group with ebastine in the lead. Ebastine is a second-
generation H1R antagonist free of any significant influence on the 
central nervous system as it does not penetrate the blood-brain bar-
rier.75 The occurrence rate of the most common adverse events such 
as drowsiness, headache and dry mouth is comparable to placebos. 
Ebastine showed a satisfactory utility in abating the symptoms of al-
lergic rhinitis and chronic idiopathic urticaria.75 Smaller studies also 
indicate its possible use in cold urticaria, atopic asthma, mosquito 
bites, and the common cold (with pseudoephedrine).76-79 Additional 
advantages include the once-daily administration, pharmacokinetics 
independent of food intake, and availability of a novel formula-
tion––fast dissolving tablet––which does not require the aid of a 
drink. Currently, there is an ongoing multicenter trial assessing the 
efficacy of ebastine in patients with IBS (ClinicalTrials.gov Identi-
fier: NCT01908465). 
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Conclusions and Future Perspectives  
The following questions remain unanswered: should we focus 
more on histamine receptors in IBS? The answer cannot come as a 
simple binary result but requires further elaboration. We already use 
MCs as a target, though in a rather indirect way. McIntosh et al80 
recently reported that diets low in fermentable oligosaccharides, di-
saccharides, mono-saccharides, and polyols (FODMAPs) changes 
the metabolome, significantly reducing histamine levels in the urine. 
Consequently, by administering the diet low in FODMAPs we 
could modulate the histamine levels in patients with IBS thus alter-
ing the symptoms. Although histamine is not the only mediator 
found to be implicated in the pathogenesis of IBS, it is evident that 
this biogenic amine is pathologically of great importance.
In conclusion, HR antagonists are definitely worth being con-
sidered as potential therapeutic agents in treating IBS, especially the 
second generation agents which lack activity in the central nervous 
system, but display a considerably safe profile. Larger studies on 
ebastine will reveal the efficacy of H1R antagonists in patients with 
IBS. For other HR compounds like ketotifen, famotidine, raniti-
dine, and AST-120, there is already evidence from clinical trials 
in patients with IBS that suggest that their use may be beneficial. 
However, until the mechanisms of action of these compounds are 
elucidated the possibility of using HRs-targeting agents remains 
speculative. 
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